Finch Therapeutics Group, Inc. is a pioneering company based in Boston, MA, specializing in the field of microbiome therapeutics. With a robust intellectual property estate and a portfolio of innovative microbiome assets, Finch is at the forefront of developing new modalities for a wide range of product strategies and therapeutic areas.
As an early pioneer in the microbiome field, Finch has leveraged insights from human microbiota transplantation studies to establish a leading portfolio of microbiome assets. Their decision to discontinue the Phase 3 trial of CP101 in recurrent C. difficile reflects their focus on realizing the value of their IP estate and other assets, positioning them as a key player in the exciting and rapidly evolving field of microbiome therapeutics.
Generated from the website